Q32 Bio ($QTTB) Stock Hub: SIGNAL-AA Data, $200M Financing and the 2027 Registrational Path

01 01 · Executive summary

Q32 Bio has crossed the first major clinical hurdle in its rebuilt equity story. On July 13, 2026, the company reported positive 36-week topline results from Part B of SIGNAL-AA, an open-label Phase 2a study of bempikibart in 33 patients with severe or very severe alopecia areata. The prespecified modified intent-to-treat analysis showed a 35.3% mean reduction in SALT score from baseline. Ten of 25 mITT patients, or 40.0%, reached SALT-20 at Week 36. In the full 33-patient intent-to-treat population, the same ten responders translated into a 30.3% SALT-20 rate.^[1]

The readout was clinically encouraging but not definitive. Part B had no placebo arm, the dataset was small, and eight enrolled patients were excluded from the mITT efficacy population under prespecified criteria. Five had discontinued before Week 18 and three were classified as having unstable disease; the company presentation states that none of the early discontinuations was related to bempikibart safety. This does not invalidate the mITT analysis, but it makes the ITT result and the reasons for exclusion central to a balanced interpretation.^[2]

The financial picture then changed dramatically. Q32 Bio priced an underwritten offering of 6,027,399 common shares and pre-funded warrants covering 4,931,506 shares at an effective public price of $18.25 per share-equivalent. Gross proceeds were approximately $200 million, with estimated net proceeds of approximately $187.6 million before any greenshoe exercise. The underwriters received a 30-day option for up to 1,643,835 additional common shares.^[7][8]

The result is a much stronger funding position but also a much larger capital base. The prospectus calculated 29,708,814 common shares outstanding immediately after the offering, assuming no exercise of the new pre-funded warrants or underwriters’ option. Adding the 4.93 million new pre-funded warrants produces approximately 34.64 million immediate share-equivalents; including older pre-funded warrants disclosed in the prospectus raises the potential equivalent count further. The financing largely removes near-term balance-sheet stress, but it does not remove dilution as an analytical issue.

The next phase is less binary and more operational. Q32 must complete the Week 52 off-drug follow-up, continue the open-label extension, present the full Part B dataset, obtain FDA alignment on the registration strategy, define dose and maintenance schedule, and start a controlled registration-directed program in the first half of 2027. The new capital gives the company room to do this. It does not guarantee that the Phase 2 signal will reproduce in a larger randomized trial.

02 02 · What changed after the July 13 readout

The original version of this coverage treated the 36-week data as the current catalyst and used the March 31 balance sheet as the main financial reference. That is no longer sufficient. Four developments now define the updated QTTB setup.

One verification point that remains open

The final prospectus and underwriting agreement establish the offering terms and identify July 16 as the expected closing date. As of August 1, the company IR page reviewed for this update did not show a separate closing press release or a separate disclosure confirming whether the 1.64 million-share underwriters’ option had been exercised. The hub therefore uses the base offering figures and labels the greenshoe as unresolved.

03 03 · SIGNAL-AA Part B: what the 36-week data showed

Part B enrolled 33 patients with severe or very severe alopecia areata, defined by baseline SALT scores of 50 to 100 and a current disease episode lasting no more than four years. Prior oral JAK inhibitor use was permitted; 36.4% of enrolled patients had previously received an oral JAK inhibitor. Patients received 200 mg of subcutaneous bempikibart weekly for four loading doses and then 200 mg every other week for 32 additional weeks, for 36 weeks of active treatment. Off-drug follow-up continues through Week 52 before optional open-label-extension enrollment.^[1]

Week 36 responder analysis

Company-reported prespecified analyses. Percentages cannot be compared directly with other trials because designs, populations and time points differ.

The response curve in the company presentation continued to deepen through Week 36. That trajectory supports the 36-week dosing duration and argues against judging a biologic solely at an earlier 12- or 24-week point. It also raises a practical question for pivotal development: whether continued dosing beyond Week 36 produces further incremental benefit and what maintenance schedule is necessary to preserve it.

04 04 · The denominator matters: mITT versus ITT

The headline efficacy number is based on a 25-patient modified intent-to-treat population, not all 33 enrolled patients. The company presentation states that the mITT population excluded five early-termination patients who discontinued before Week 18, including two who had no post-baseline SALT assessment, and three patients with unstable disease under prespecified statistical-analysis-plan criteria. It also states that none of the five early terminations was related to bempikibart safety.^[2]

This distinction is not a technical footnote. In the mITT group, 10 responders produce a 40.0% SALT-20 rate. Across all 33 enrolled patients, the same ten responders produce a 30.3% rate. Both numbers are valid for their stated analysis populations, but they answer different questions.

How to read the two populations

• mITT asks: among patients who met the prespecified evaluability rules, how much activity was observed?
• ITT asks: among everyone enrolled, regardless of early discontinuation or later evaluability, what proportion achieved the endpoint?
• The pivotal test: a larger randomized study must show that efficacy remains convincing under a stricter controlled framework with transparent handling of missing data and discontinuations.

The mITT result is not automatically inflated or inappropriate; modified populations are common in exploratory development when prespecified. The analytical risk arises when readers focus only on the 40.0% figure and ignore the full-enrollment denominator, the absence of placebo and the small number of patients. A rigorous view keeps all three in the same frame.

05 05 · Durability, safety and pharmacology

Early off-drug durability

The company reported maintenance or deepening of response in multiple patients after dosing stopped. One patient moved from SALT-10 at Week 36 to SALT-0 at Week 44 and maintained the result through Week 52 before entering the extension. Other illustrated cases maintained SALT-20 or deepened to SALT-10 during the 16-week off-drug period. These examples are clinically interesting, but they are individual cases rather than a controlled estimate of the probability or duration of remission across the entire study.^[2]

Part A’s open-label extension also contributes to the durability discussion. Eight patients entered after 26 to 55 weeks off treatment, including prior responders, non-responders and placebo patients. Q32 reported that re-dosing was generally well tolerated and that patients who had retained hair at extension entry showed durable or further growth. At the same time, management concluded that the totality of the data supports a maintenance regimen rather than very long drug-free intervals.

Safety profile

No new safety signals were reported in Part B. There were no serious adverse events and no Grade 3 or higher adverse events related to treatment. Injection-site reactions were the most common treatment-emergent event, affecting 36.3% of patients, but represented approximately 4% of all administered doses. The company described all reported injection-site reactions as mild and self-resolving without intervention, with most resolving within one day.^[1]

PK, PD and immunogenicity

The loading regimen achieved steady-state drug concentrations approximately ten weeks earlier than Part A. The presentation reported roughly threefold higher trough concentrations during the first month versus Part A and negligible anti-drug antibodies without a meaningful effect on pharmacokinetics. This supports the revised loading strategy, although late-stage development still has to establish the optimal balance between exposure, efficacy, convenience and long-term safety.

What the data do not establish yet

The readout does not establish placebo-adjusted efficacy, comparative efficacy versus an approved JAK inhibitor, long-term safety in a large population, a commercial maintenance schedule, pediatric efficacy, efficacy in moderate disease or a durable treatment-free remission rate. Those are future-development questions, not missing decorations around an already completed proof.

06 06 · The science: why bempikibart is different

Bempikibart, formerly known as ADX-914, is a fully human monoclonal antibody directed against the alpha chain of the interleukin-7 receptor, IL-7Rα. The receptor is shared by the IL-7 and thymic stromal lymphopoietin pathways. Blocking IL-7Rα is therefore designed to interrupt two upstream immune signals implicated in T-cell survival, activation and inflammatory disease biology.

Alopecia areata is driven by an immune attack on the hair follicle. Current oral JAK inhibitors intervene downstream in intracellular cytokine signaling. Bempikibart instead aims to modulate an upstream receptor with a subcutaneous biologic. The hoped-for commercial differentiation is not merely “another effective drug,” but a combination of efficacy, a potentially cleaner long-term safety profile, limited monitoring burden and a maintenance schedule that could be less frequent than daily oral therapy.

The strategic target product profile

Q32 is positioning bempikibart as a selective, non-JAK biologic that could deliver meaningful regrowth without the class-related boxed-warning framework carried by approved oral JAK inhibitors. That is a development objective, not an established label advantage: only a large controlled safety database and eventual regulatory review can determine the final risk language.

Q32 regained full development and commercial rights to bempikibart after terminating a prior collaboration with Horizon. The retained rights are economically important, but the termination agreement includes potential regulatory and sales milestone obligations to Horizon of up to an aggregate $75.1 million upon specified achievements. That future obligation should be part of any long-duration commercial valuation rather than treated as current operating debt.^[18]

07 07 · Regulatory and clinical path: what must happen next

The company says the totality of SIGNAL-AA supports advancement into a registration-directed program and plans to engage the FDA on the proposed design, with initiation targeted for the first half of 2027. Full Part B results are expected at a future medical meeting, but Q32 had not named the meeting or disclosed a presentation date as of August 1.^[2]

The July financing makes this roadmap more credible because Q32 can enter FDA discussions and prepare a larger program without an immediate financing cliff. It also changes management’s capital-allocation challenge. The company now has the option to evaluate moderate and pediatric AA populations and additional immune-and-inflammatory indications, but expanding too quickly could dilute focus and increase burn before the core severe-AA program is fully de-risked.

08 08 · Alopecia areata market and competitive landscape

Alopecia areata can range from patchy hair loss to complete scalp loss and loss across the body. Q32 cites approximately 700,000 people living with the disease in the United States; its July presentation used a broader estimate of approximately 800,000, with roughly 530,000 potentially addressable and approximately 300,000 treated with advanced therapies. Those figures are company-sponsored market estimates and should not be confused with a guaranteed treated population or a revenue forecast.

The competitive benchmark has become more demanding. Three oral JAK inhibitors are available in the United States for severe alopecia areata: baricitinib, ritlecitinib and deuruxolitinib. Their existence validates the commercial market and the SALT endpoint, but it also means bempikibart must show a clear reason for physicians and patients to choose an injectable biologic.

Cross-trial comparisons are especially hazardous here. SIGNAL-AA Part B was small and open-label, while approval trials for the JAK inhibitors were randomized and placebo-controlled, used different treatment durations and enrolled different populations. The correct late-stage question is not whether one topline percentage looks numerically larger than another. It is whether bempikibart can reproduce clinically meaningful SALT responses versus placebo with an attractive risk-benefit profile and practical dosing.

09 09 · Financial position before the July financing

Q32 Bio reported $50.8 million in cash and cash equivalents at March 31, 2026. That figure excluded $14.2 million of gross ATM proceeds received after quarter-end. First-quarter net loss was $7.6 million, or $0.54 per share, compared with $11.0 million and $0.90 per share in the prior-year quarter. R&D expense fell to $3.2 million from $7.1 million, while G&A declined to $4.5 million from $5.1 million. The lower cost base reflected the restructuring and the sale of ADX-097.^[4]

The May 5 guidance stated that March cash, guaranteed near-term ADX-097 payments and post-quarter ATM proceeds were expected to fund operations into the first half of 2028. That remains the last formal runway guidance located for this update, but it predates both the $55 million May PIPE and the $200 million July offering. It should therefore be read as a stale lower baseline, not a current forecast of where the enlarged balance sheet runs out.

Debt payoff

On June 24, Q32 paid approximately $6.8 million to repay the remaining balance under its Silicon Valley Bank loan agreement and terminated the facility. The March 31 balance sheet had shown $8.2 million of venture debt; the later payoff removes that liability and the associated covenants from the forward capital structure.^[8]

Why there is no “current cash” tile above $250M

Adding March cash, announced financings and subtracting debt produces a useful liquidity bridge, but not a reported cash balance. It would ignore underwriting and PIPE expenses, operating burn since March, working-capital movements and the timing of proceeds. Until Q32 files the second-quarter balance sheet or gives updated guidance, the honest formulation is: reported cash was $50.8 million at March 31, and subsequent transactions materially increased it.

10 10 · The $200M public offering: terms and implications

On July 14, Q32 priced 6,027,399 common shares at $18.25 and pre-funded warrants covering 4,931,506 common shares at $18.2499, with a nominal $0.0001 exercise price. All securities were sold by the company. Morgan Stanley, Jefferies and Cantor acted as joint book-running managers; Oppenheimer also acted as a book-running manager and H.C. Wainwright as lead manager.^[7]

The offering generated approximately $200 million of gross proceeds. The final prospectus estimated net proceeds of $187.59 million after underwriting discounts, commissions and estimated expenses. If the underwriters exercise their option for the full 1,643,835 additional shares, estimated net proceeds would rise to approximately $215.79 million.^[8]

2026 financing sequence

Gross amounts unless explicitly stated. The July bar shows announced gross proceeds; estimated July net proceeds were approximately $187.6M.

Use of proceeds

Q32 stated that the proceeds, together with existing cash, would be used for working capital, research, clinical development and commercialization efforts, including advancement of bempikibart into future clinical trials. The prospectus gives management broad discretion and does not allocate a fixed dollar amount to the registration-directed program.

The remaining ATM

The final prospectus stated that $75 million remained available under the Cantor ATM agreement as of the prospectus date. It also included a 45-day restricted period under which the company, directors, officers and certain affiliates agreed not to issue or sell specified securities without the underwriters’ consent, subject to stated exceptions. The ATM is therefore a future financing tool and dilution capacity, not evidence that another sale is imminent.^[8]

11 11 · Capital structure: stronger balance sheet, larger denominator

The July financing transformed the share count. The prospectus starts from 14,629,463 common shares outstanding at March 31, then gives effect to 6,725,000 common shares issued in the May PIPE and 2,326,952 shares sold through the ATM through the prospectus date. Adding the 6,027,399 common shares in the July offering produces 29,708,814 basic common shares immediately after the offering, before exercise of new pre-funded warrants or the underwriters’ option.

Common-share and immediate share-equivalent expansion

Illustrative bridge using the final prospectus. “Equivalent” columns include nominal-exercise pre-funded warrants and should not be confused with reported basic shares outstanding.

The July prospectus also disclosed 1,025,654 older pre-funded warrants outstanding at March 31 and 150,000 pre-funded warrants from the May PIPE, plus options, RSUs and other warrants. Including the older pre-funded warrants with the July share-equivalent figure brings the potential common-equivalent count to approximately 35.82 million before options, RSUs, other warrants and any greenshoe exercise.

Dilution is no longer a liquidity emergency; it is a valuation denominator

Before the clinical readout, dilution risk was tied to whether Q32 could fund the next stage. After the offering, the company is much better financed, but each future enterprise-value estimate must be divided across a substantially larger share-equivalent base. The balance-sheet improvement is real, and so is the denominator expansion.

The July 28 resale prospectus

On July 28, Q32 filed a prospectus covering potential resale by May PIPE investors of 6,875,000 shares: 6,725,000 issued common shares plus 150,000 shares underlying pre-funded warrants. Q32 will not receive proceeds from those secondary sales. This is not a new capital raise and does not by itself create additional dilution beyond the securities already issued or committed in May. It does, however, make those securities available for resale and can influence technical supply.^[9]

12 12 · ADX-097 optionality and retained complement assets

Q32 sold substantially all assets related to ADX-097 to Akebia Therapeutics in November 2025. The consideration included $7 million at closing, $3 million at the six-month anniversary and $2 million upon the earlier of the first milestone or December 31, 2026. Beyond those $12 million of upfront and near-term payments, Q32 is eligible for up to $580 million of additional development, regulatory and commercial milestones and tiered royalties ranging from low single digits to mid-teens on potential annual net sales.^[10]

This creates non-dilutive optionality, but the milestones are contingent and should not be treated as cash, receivables or base-case value. Akebia controls future ADX-097 development, and Q32’s economics depend on another company advancing the program successfully.

Q32 retained its tissue-targeted complement platform, including ADX-096 and other early-stage assets, and has said it is evaluating strategic options. The equity story is therefore not literally a one-asset legal entity. In practical valuation terms, however, bempikibart remains the dominant internally controlled clinical value driver.

13 13 · Analyst reaction after the data

The July 13 readout triggered a broad upward reset in sell-side expectations. These actions are useful as a record of how external models changed, but they are opinions based on assumptions about probability of success, market penetration, pricing, timelines and future dilution. They are not company guidance and are not Merlintrader targets.

The dispersion is notable. A target range from $36 to $66 implies materially different views on pivotal probability, peak sales, commercial duration and share count. The most useful signal is not the headline target itself, but the common analytical shift: the Phase 2 readout increased perceived clinical probability, and the financing reduced near-term funding risk. The unresolved issue is whether those higher assumptions survive a controlled registrational dataset.

14 14 · Price action and retail sentiment

QTTB closed at $11.21 on July 10, before the data. It closed at $21.37 on July 13 after the positive readout, then retreated as the financing was announced and priced. By July 31 the stock closed at $15.68. The move illustrates a familiar biotech pattern: clinical de-risking can increase the enterprise value while a rapid financing absorbs part of the price shock and resets the share base.

Selected daily closes around the catalyst

July 10-July 31, 2026. Delayed market data; line is editorial and not a technical signal.

Stocktwits snapshot

Retail attention spiked around the catalyst and then faded quickly. Stocktwits’ normalized message-volume score reached “Extremely High” from July 13 through July 21, then fell to 3/100, “Extremely Low,” by July 31. Normalized sentiment reached 98/100 on July 14, then declined to 44/100, “Slightly Bearish,” by July 31. The current low-volume signal suggests that the immediate event-trading phase had cooled substantially by month-end.

Sentiment disclaimer

Stocktwits posts and normalized scores represent comments and behavior from retail traders, not professional clinical analysis. They can help describe attention, positioning and narrative shifts, but they do not validate trial results or estimate intrinsic value.

15 15 · Management, investors and execution

Q32 Bio is led by chief executive officer Jodie Morrison. Lee Kalowski serves as president and chief financial officer, and co-founder Shelia Violette, Ph.D., serves as chief scientific officer. The management team’s recent execution record includes completing SIGNAL-AA Part B enrollment, delivering the Week 36 readout, selling ADX-097 for non-dilutive contingent economics, completing multiple financings at progressively higher prices and removing venture debt.

The May $55 million private placement was led by BVF Partners with participation from RA Capital Management, OrbiMed and Atlas Venture. Their participation indicates specialist interest and access to experienced biotech capital. It does not guarantee clinical success, and the July 28 resale registration means the May securities can become market supply.

The July financing also raises the standard by which execution should be judged. A company with roughly $188 million of estimated new net proceeds has fewer excuses for avoidable delay, weak trial design, premature pipeline expansion or inefficient spending. The focus shifts from “can Q32 finance the next step?” to “can management convert capital into a high-quality, regulator-aligned program?”

16 16 · Merlintrader Health Score

The Merlintrader Health Score summarizes 12-18 month financial and operational robustness. It is not a valuation, price target, trading signal or recommendation. The score has been updated from 3.7 to 3.9 because the July financing and debt payoff sharply improve balance-sheet resilience, while the much larger share-equivalent base keeps dilution as a major negative pillar.

The weighted score is approximately 3.86 and is rounded to 3.9. The score can fall even with a strong cash balance if trial execution slips, the pivotal design disappoints or capital is deployed too broadly before the core program is validated.

17 17 · Catalyst timeline

ADX-097 sold to Akebia

$12M of upfront and near-term consideration, up to $580M of additional milestones and tiered royalties; Q32 retains other complement-platform assets.

Restructuring and $10.5M registered direct offering

Resources concentrated on bempikibart in alopecia areata.

Q1 financial results

$50.8M cash at March 31, excluding $14.2M of gross ATM proceeds received after quarter-end; formal runway guidance into 1H28.

$55M specialist-led PIPE

6.725M common shares at $8.00 and 150,000 pre-funded warrants at $7.9999.

SVB loan repaid

Approximately $6.8M remaining balance paid and loan agreement terminated.

Positive SIGNAL-AA Part B topline

35.3% mean SALT reduction in mITT; 40.0% mITT and 30.3% ITT SALT-20; favorable reported safety and early durability signals.

$200M public offering

Offering priced at $18.25 per share-equivalent; estimated base net proceeds approximately $187.6M.

May PIPE resale registration

Prospectus covers 6.875M already issued or committed May securities; no proceeds to Q32 from secondary sales.

Full Part B presentation

Management plans to present the complete dataset at a future medical meeting.

Week 52 off-drug follow-up and OLE

Durability, re-dosing and maintenance-schedule data remain important to the product profile.

FDA engagement

The proposed registration-directed design must be aligned with regulators; timing and outcome are not yet public.

Targeted registration-directed initiation

The next major execution milestone and the point where trial scale, burn and regulatory requirements become clearer.

18 18 · Risks and red flags

Open-label Phase 2 evidence

Part B had no placebo arm. Spontaneous regrowth, disease variability, investigator expectations and selection effects cannot be separated as rigorously as in a randomized controlled trial.

Small study and analysis-population gap

Only 33 patients were enrolled and 25 were included in mITT efficacy analyses. The SALT-20 rate is 40.0% in mITT but 30.3% in ITT. Late-stage success depends on reproducibility across a much larger population.

Single dominant internal value driver

Q32 retains other assets and ADX-097 economics, but bempikibart remains the dominant controlled clinical program. A pivotal failure, safety issue or regulatory delay would affect most of the current thesis.

Capital structure and supply

Basic shares more than doubled versus March 31 after the May PIPE, ATM and July common issuance. New and older pre-funded warrants, options, RSUs, the possible greenshoe and the remaining ATM create additional share-equivalent and future-supply considerations.

Competition is already commercial

Approved oral JAK inhibitors have established prescribing pathways, efficacy expectations and payer relationships. Bempikibart must justify an injectable route through meaningful safety, durability, convenience or efficacy differentiation.

Runway may encourage over-expansion

The stronger balance sheet enables additional indications and populations, but premature expansion could raise burn and distract from the core registrational program.

Contingent obligations and milestones

ADX-097 milestones are not guaranteed assets, while bempikibart’s regained rights carry potential Horizon regulatory and sales milestone obligations. Long-term models must include both contingent upside and contingent payments.

19 19 · Bull / base / bear scenarios

These scenarios are analytical frameworks, not forecasts, recommendations or price targets.

Bull scenario

Week 52 and OLE data strengthen the durability narrative; FDA feedback supports a clean registrational path; the pivotal design preserves the favorable dose and safety profile; controlled efficacy approaches or exceeds the clinically meaningful Phase 2 signal. The enlarged balance sheet funds execution without another near-term equity raise, and bempikibart earns a credible position as a non-JAK first-line biologic.

Base scenario

The Phase 2 data justify late-stage development but remain exploratory. Q32 starts a controlled program in 1H27, burn rises materially and the market waits for placebo-adjusted evidence. The financing removes immediate survival risk, while the larger denominator and long timeline limit enthusiasm until trial design and enrollment become clearer.

Bear scenario

FDA feedback requires a larger, longer or more complex program than expected; durability is less consistent in the full dataset; controlled efficacy falls below the open-label signal or safety differentiation narrows. The company spends aggressively across populations or indications, and the substantial post-financing share base magnifies disappointment.

20 20 · Bottom line

Q32 Bio is in a materially stronger position than it was before July 13. Bempikibart produced a credible Phase 2a activity signal in severe and very severe alopecia areata, with a favorable reported safety profile and early examples of off-drug durability. The company then converted the clinical momentum into approximately $200 million of gross financing at $18.25 per share-equivalent and removed its venture debt.

The cleanest bullish fact is no longer just the 35.3% mean SALT reduction. It is that Q32 now has the capital to design and initiate the next program without negotiating from financial weakness. The cleanest caution is no longer simply “biotech dilution may come.” Dilution has already happened at scale, and the key question is whether the newly funded registrational effort creates enough clinical value to justify the much larger share-equivalent base.

21 21 · Frequently asked questions

At Week 36, Q32 reported a 35.3% mean SALT reduction in the prespecified mITT population. Ten of 25 mITT patients, or 40.0%, reached SALT-20. In the full 33-patient ITT population, the rate was 30.3%.

The company presentation states that mITT excluded five patients who discontinued before Week 18 and three patients with unstable disease under prespecified criteria. None of the early discontinuations was described as related to bempikibart safety.

No. It was an open-label Phase 2a study. The lack of a randomized control group is one of the main limitations and must be addressed in registration-directed development.

The company priced an approximately $200 million gross underwritten public offering. The final prospectus estimated approximately $187.6 million of net proceeds before any exercise of the underwriters’ option.

The final prospectus calculated 29,708,814 common shares immediately after the base offering, assuming no exercise of the new pre-funded warrants or greenshoe. The new pre-funded warrants cover another 4,931,506 common shares, producing approximately 34.64 million immediate share-equivalents before older pre-funded warrants, options, RSUs and other securities.

No. It registered potential resale of 6.875 million May PIPE securities by selling stockholders. Q32 receives no proceeds from those secondary sales. The filing can affect supply, but it does not represent a new July 28 capital raise.

The company plans to complete Week 52 follow-up and the open-label extension, present full Part B data at a future medical meeting, engage the FDA and initiate a registration-directed program in the first half of 2027. Exact dates for the medical presentation and FDA interaction were not announced as of August 1.

Yes. It retains ADX-096 and other early complement-platform assets and has contingent milestones and royalties from the sale of ADX-097 to Akebia. Bempikibart remains the dominant internally controlled clinical value driver.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

22 22 · Primary and verification sources

1. Q32 Bio — positive 36-week topline results from SIGNAL-AA Part B, July 13, 2026.
2. Q32 Bio — SIGNAL-AA Part B 36-week investor presentation, data cutoff June 30, 2026.
3. SEC — Form 8-K furnishing the July 13 SIGNAL-AA results.
4. Q32 Bio — first-quarter 2026 financial results and corporate update.
5. SEC — Q32 Bio Form 10-Q for the quarter ended March 31, 2026.
6. Q32 Bio — $55 million private placement announced May 27, 2026.
7. Q32 Bio — pricing of the $200 million public offering, July 14, 2026.
8. SEC — final prospectus supplement for the July 2026 public offering.
9. SEC / Q32 Bio — July 28, 2026 resale prospectus covering May PIPE securities.
10. SEC — Form 8-K describing the ADX-097 asset sale to Akebia, milestones and royalties.
11. Q32 Bio — closing of the Homology Medicines merger and 2024 private placement.
12. FDA — 2022 approval of Olumiant for severe alopecia areata.
13. FDA — Litfulo drug-trial snapshot and indication.
14. Sun Pharma — LEQSELVI US approval and launch releases.
15. The Fly / TipRanks — Wells Fargo rating action, July 13, 2026.
16. The Fly / TipRanks — Mizuho target action, July 13, 2026.
17. The Fly / TipRanks — Oppenheimer target action, July 13, 2026.
18. SEC — Q32 Bio Form 10-K disclosure concerning retained bempikibart rights and potential Horizon milestone obligations.
19. Stocktwits QTTB stream — retail sentiment and message-volume snapshot captured July 31, 2026; this is a non-professional sentiment source.

Market-price verification: delayed consolidated-market snapshot for July 31, 2026, cross-checked with historical daily bars. Company IR and SEC filings were reviewed through August 4, 2026. No separate official confirmation of greenshoe exercise was located by the cutoff.